KEGG   DRUG: Emtricitabine, rilpivirine and tenofovir alafenamideHelp
Entry
D10836            Mixture   Drug                                   

Name
Emtricitabine, rilpivirine and tenofovir alafenamide;
Odefsey (TN)
Product
Component
Emtricitabine [DR:D01199], (Rilpivirine hydrochloride [DR:D09958] | Rilpivirine [DR:D09720]), (Tenofovir alafenamide fumarate [DR:D10605] | Tenofovir alafenamide [DR:D10428])
Remark
Therapeutic category: 6250
ATC code: J05AR19
Product: D10836<JP/US>
Efficacy
Antiviral
  Disease
HIV-1 infection [DS:H01563]
Comment
Rilpivirine is primarily metabolized by CYP3A.
Tenofovir alafenamide is a substrate of cathepsin A, CYP3A and P-gp.
Metabolism
Enzyme: CTSA [HSA:5476], CYP3A [HSA:1576 1577 1551]
Transporter: ABCB1 [HSA:5243]
Interaction
Drug interaction
Brite
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
 J ANTIINFECTIVES FOR SYSTEMIC USE
  J05 ANTIVIRALS FOR SYSTEMIC USE
   J05A DIRECT ACTING ANTIVIRALS
    J05AR Antivirals for treatment of HIV infections, combinations
     J05AR19 Emtricitabine, tenofoviralafenamide and rilpivirine
      D10836  Emtricitabine, rilpivirine and tenofovir alafenamide <JP/US>
USP drug classification [BR:br08302]
 Antivirals
  Anti-HIV Agents, Other
   Emtricitabine/ Rilpivirine/ Tenofovir Alafenamide Fumarate
    D10836  Emtricitabine, rilpivirine and tenofovir alafenamide
Therapeutic category of drugs in Japan [BR:br08301]
 6  Agents against pathologic organisms and parasites
  62  Chemotherapeutics
   625  Antivirals
    6250  Antivirals
     D10836  Emtricitabine, rilpivirine and tenofovir alafenamide
Antiinfectives [br08350.html]
 Antivirals
  D10836
New drug approvals in Europe [br08329.html]
 European public assessment reports (EPAR) authorised medicine
  D10836
BRITE hierarchy
Other DBs
PubChem: 319902636
LinkDB All DBs

» Japanese version   » Back

DBGET integrated database retrieval system